Javascript must be enabled to continue!
Role of the Hematocrit in a Rabbit Model of Arterial Thrombosis and Bleeding
View through CrossRef
Background
A decrease in hematocrit lengthens bleeding time. The authors studied the role of hematocrit variations in an experimental model of arterial thrombosis and bleeding.
Methods
The Folts model was used in 24 rabbits. After anesthesia was induced and common monitors were positioned, the right common carotid artery was exposed and a 60% stenosis was induced. A compression injury of the artery was then produced, which triggered a series of cyclic episodes of thrombosis and clot lysis (cyclic flow reductions [CFRs]). After counting the number of CFRs that occurred in 20 min (CFR1), the animals were assigned randomly to one of three groups (n = 8 in each group): control, hemodilution with rabbit homologous platelet-rich plasma, and hemodilution with gelatin solution and then reinfusion of the shed blood. The effect of hemodilution with replacement by platelet-rich plasma or by colloid was observed by recording the number of CFRs during another 20-min period (CFR2). A third period of observation (CFR3) followed shed blood reinfusion in the gelatin solution group. Ear immersion bleeding time was recorded after each CFR period.
Results
In the two experimental groups, the decrease in hematocrit (from 36 +/- 3% to 23 +/- 2% and from 38 +/- 3% to 23 +/- 2%, respectively; mean +/- SD) abolished CFRs (from a median of 4 to 0 and 7 to 0, respectively) and significantly lengthened bleeding time (from 76 +/- 24 s to 114 +/- 36 s and from 84 +/- 37 s to 127 +/- 29 s, respectively). Blood reinfusion in the group that received the gelatin solution caused CFR to reappear (CFR3 = 4).
Conclusions
Decreases in hematocrit reduced the cyclic arterial thrombosis rate and increased the bleeding time in the rabbits in this study. Hematocrit normalization caused thrombosis to reappear.
Ovid Technologies (Wolters Kluwer Health)
Title: Role of the Hematocrit in a Rabbit Model of Arterial Thrombosis and Bleeding
Description:
Background
A decrease in hematocrit lengthens bleeding time.
The authors studied the role of hematocrit variations in an experimental model of arterial thrombosis and bleeding.
Methods
The Folts model was used in 24 rabbits.
After anesthesia was induced and common monitors were positioned, the right common carotid artery was exposed and a 60% stenosis was induced.
A compression injury of the artery was then produced, which triggered a series of cyclic episodes of thrombosis and clot lysis (cyclic flow reductions [CFRs]).
After counting the number of CFRs that occurred in 20 min (CFR1), the animals were assigned randomly to one of three groups (n = 8 in each group): control, hemodilution with rabbit homologous platelet-rich plasma, and hemodilution with gelatin solution and then reinfusion of the shed blood.
The effect of hemodilution with replacement by platelet-rich plasma or by colloid was observed by recording the number of CFRs during another 20-min period (CFR2).
A third period of observation (CFR3) followed shed blood reinfusion in the gelatin solution group.
Ear immersion bleeding time was recorded after each CFR period.
Results
In the two experimental groups, the decrease in hematocrit (from 36 +/- 3% to 23 +/- 2% and from 38 +/- 3% to 23 +/- 2%, respectively; mean +/- SD) abolished CFRs (from a median of 4 to 0 and 7 to 0, respectively) and significantly lengthened bleeding time (from 76 +/- 24 s to 114 +/- 36 s and from 84 +/- 37 s to 127 +/- 29 s, respectively).
Blood reinfusion in the group that received the gelatin solution caused CFR to reappear (CFR3 = 4).
Conclusions
Decreases in hematocrit reduced the cyclic arterial thrombosis rate and increased the bleeding time in the rabbits in this study.
Hematocrit normalization caused thrombosis to reappear.
Related Results
Cometary Physics Laboratory: spectrophotometric experiments
Cometary Physics Laboratory: spectrophotometric experiments
<p><strong><span dir="ltr" role="presentation">1. Introduction</span></strong&...
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Bleeding Risk Factors in Thrombocytopenic Patients with Hematologic Malignancies
Introduction
Despite prophylactic platelet transfusions, World Health Organization (WHO) grade ≥ 2 bleeding occurs in 50 to 70% of patients with hematologic malignan...
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Edoxaban and Cancer-Associated Venous Thromboembolism: A Meta-analysis of Clinical Trials
Abstract
Introduction
Cancer patients face a venous thromboembolism (VTE) risk that is up to 50 times higher compared to individuals without cancer. In 2010, direct oral anticoagul...
Risk Factors for Umbilical Venous Catheter-Associated Thrombosis in Very Low Birth Weight Infants.
Risk Factors for Umbilical Venous Catheter-Associated Thrombosis in Very Low Birth Weight Infants.
Abstract
Background: Thrombosis in neonates is a rare but serious occurrence that is usually associated with central catheterization. Among acquired risk factors, th...
Association of Genetic Variability in Selected Genes with Platelet Hyperaggregability and Arterial Thrombosis
Association of Genetic Variability in Selected Genes with Platelet Hyperaggregability and Arterial Thrombosis
Abstract
Introduction: Inherited platelet hyperaggregability, so called “Sticky platelet syndrome” (SPS), is a prothrombotic platelet disorder. Th...
Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience
Bleeding Disorder Referrals to Hematology Clinic: A Single Institution Experience
BACKGROUND
Our tertiary care pediatric hematology/oncology/BMT service receives hundreds of referrals yearly for bleeding disorder evaluation both due to bleeding sy...
Detecting Bleeding Risk in Patients Taking Vitamin K Antagonists Using Thrombin Generation Tests
Detecting Bleeding Risk in Patients Taking Vitamin K Antagonists Using Thrombin Generation Tests
Abstract
Introduction:
During the last 50 years vitamin K antagonists (VKAs) have been widely used for the primary prevention of thromboembolism in pa...
Thrombosis in systemic lupus erythematosus patients: analysis of COMOSLE-Egypt study population
Thrombosis in systemic lupus erythematosus patients: analysis of COMOSLE-Egypt study population
Introduction. Thrombosis is prevalent in patients with systemic lupus erythematosus (SLE). However, studies focusing on the impact of thrombosis on damage and survival are still in...

